{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dialysis-dependent+Chronic+Kidney+Disease",
    "query": {
      "condition": "Dialysis-dependent Chronic Kidney Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dialysis-dependent+Chronic+Kidney+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T05:16:48.930Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03799627",
      "title": "Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Dialysis-dependent Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Vadadustat",
          "type": "DRUG"
        },
        {
          "name": "Epoetin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Vadadustat TIW",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 175,
      "start_date": "2019-01-31",
      "completion_date": "2020-07-15",
      "has_results": true,
      "last_update_posted_date": "2022-09-29",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 41,
      "location_summary": "Fresno, California • Granada Hills, California • Los Angeles, California + 32 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03799627"
    },
    {
      "nct_id": "NCT00255424",
      "title": "Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "ferumoxytol or oral iron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 304,
      "start_date": "2004-05",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2015-01-09",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 19,
      "location_summary": "Encino, California • Riverside, California • Tarzana, California + 15 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00255424"
    },
    {
      "nct_id": "NCT03236246",
      "title": "KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Diseases",
        "Iron Deficiency Anemia"
      ],
      "interventions": [
        {
          "name": "KRX-0502",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Keryx Biopharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2017-08-15",
      "completion_date": "2019-09-27",
      "has_results": true,
      "last_update_posted_date": "2021-03-12",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Chula Vista, California • El Centro, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03236246"
    },
    {
      "nct_id": "NCT03400033",
      "title": "Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anaemia"
      ],
      "interventions": [
        {
          "name": "Daprodustat tablets",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo tablets",
          "type": "DRUG"
        },
        {
          "name": "Epoetin alfa vials",
          "type": "DRUG"
        },
        {
          "name": "Saline vials or bags",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 407,
      "start_date": "2018-09-05",
      "completion_date": "2020-06-19",
      "has_results": true,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 23,
      "location_summary": "Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Middlebury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03400033"
    },
    {
      "nct_id": "NCT01155375",
      "title": "A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Iron Deficiency Anemia"
      ],
      "interventions": [
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        },
        {
          "name": "Oral Iron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 14,
      "start_date": "2011-10-17",
      "completion_date": "2014-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 1,
      "location_summary": "Waltham, Massachusetts",
      "locations": [
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01155375"
    },
    {
      "nct_id": "NCT03140722",
      "title": "Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Dialysis-Dependent Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "vadadustat",
          "type": "DRUG"
        },
        {
          "name": "epoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2017-05-02",
      "completion_date": "2018-03-21",
      "has_results": true,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 18,
      "location_summary": "Bakersfield, California • Elk Grove, California • Encino, California + 15 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Elk Grove",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Lynwood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03140722"
    },
    {
      "nct_id": "NCT05614115",
      "title": "Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End-stage Kidney Disease",
        "Kidney Disease, Chronic",
        "Dialysis",
        "Diabetic",
        "Non-diabetic",
        "Kidney Dysfunction",
        "Kidney Failure",
        "Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2023-03-21",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05614115"
    },
    {
      "nct_id": "NCT02648347",
      "title": "Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia",
        "Non-Dialysis-Dependent Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Vadadustat",
          "type": "DRUG"
        },
        {
          "name": "Darbepoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1751,
      "start_date": "2015-12",
      "completion_date": "2020-07-31",
      "has_results": true,
      "last_update_posted_date": "2022-06-27",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 208,
      "location_summary": "Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02648347"
    },
    {
      "nct_id": "NCT00994318",
      "title": "Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Iron Deficiency Anaemia",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "FCM (Ferric carboxymaltose) high ferritin target",
          "type": "DRUG"
        },
        {
          "name": "FCM (Ferric carboxymaltose) low ferritin target",
          "type": "DRUG"
        },
        {
          "name": "Oral Iron (Ferrous sulphate)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vifor Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 626,
      "start_date": "2009-12",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2014-05-20",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 1,
      "location_summary": "Wilmington, North Carolina",
      "locations": [
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00994318"
    },
    {
      "nct_id": "NCT02680574",
      "title": "Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia",
        "Non-Dialysis-Dependent Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Vadadustat",
          "type": "DRUG"
        },
        {
          "name": "Darbepoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1725,
      "start_date": "2016-02",
      "completion_date": "2020-07-31",
      "has_results": true,
      "last_update_posted_date": "2022-06-27",
      "last_synced_at": "2026-07-23T05:16:48.930Z",
      "location_count": 219,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02680574"
    }
  ]
}